GlassScriptPhysician profile
Donna Nancy Espinosa
NPI 1841408622
$2,666.10
in general payments reported to CMS, 2019-2025
27 companies · $371 in 2025
The $371 reported for 2025 was more than what 80% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $962 · 2023: $572 · 2024: $442 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334 · Gift: $38.30 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.67 |
| Gift | $38.30 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $566.35 | 2022-2025 | Truclear, Ligasure |
| Mayne Pharma Commercial LLC | $257.33 | 2022-2025 | |
| Ascend Therapeutics US, LLC | $226.72 | 2023-2024 | |
| Agile Therapeutics, INC. | $206.37 | 2021-2024 | Twirla |
| Organon LLC | $168.25 | 2021-2023 | Nexplanon |
| Abbvie INC. | $165.01 | 2021-2023 | |
| Pfizer INC. | $143.55 | 2022-2025 | |
| Therapeuticsmd, INC. | $116.80 | 2021-2022 | |
| Aspira Women'S Health INC | $113.82 | 2022-2024 | Ova1 |
| Myovant Sciences INC. | $96.53 | 2022 | |
| Exeltis, USA INC. | $91.48 | 2021-2024 | Slynd |
| Sage Therapeutics, LLC | $72.80 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $67.74 | 2022-2025 | Aptima, Myosure Tissue Removal Device |
| Shield Therapeutics INC | $49.19 | 2023 | Accrufer |
| Ethicon US, LLC | $44.56 | 2023-2024 | Vistaseal, Surgicel Nu-Knit, Ethicon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $35.30 | 2024-2025 | Femlyv, Intrarosa |
| Amgen INC. | $30.74 | 2022 | |
| Coopersurgical, INC. | $29.87 | 2022-2023 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $25.85 | 2025 | Qelbree |
| Mycovia Pharmaceuticals, INC. | $23.54 | 2023 | Vivjoa |
| Novo Nordisk INC | $23.34 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $21.20 | 2021 | |
| Scynexis, INC. | $20.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2024 | |
| Acella Pharmaceuticals, LLC | $17.40 | 2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $16.30 | 2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $16.17 | 2025 | Stravix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.